NCT01654601已完成1 期
Clinical Trials to Compare the Pharmacokinetics Profile of DWCZP Tablet 100mg and Clozaril® Tablet 100mg After a Multi-dose Oral Administration in Schizophrenia Patients
Dong Wha Pharmaceutical Co. Ltd.5 个研究点 分布在 1 个国家目标入组 28 人开始时间: 2012年6月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 28
- 试验地点
- 5
- 主要终点
- Maximum Concentration of Clozapine in Plasma
研究概览
简要总结
To evaluate the pharmacokinetics of oral multiple-dose of DWCZP tablet 100mg.
详细描述
A randomized, 2-way crossover, open, phase I study to compare the pharmacokinetics profile of DWCZP tablet 100mg and Clozaril® tablet 100mg after a multiple-dose oral administration in schizophrenia patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult male or female within range of 20 to
- •Diagnosed as Schizophrenia (Note: Diagnosed with DSM-IV, ICD-10 as a standard Schizophrenia diagnostic tool).
- •Administered clozapine for 3 months before signing agreement with same amount daily and who can administer clozapine 100mg twice (morning, evening) a day, total of 200mg during the study time.
- •One who might be pregnant must get negative result for pregnancy test (urine or blood β-hCG) before the randomization and during the study time, one must agree appropriate contraception. However, one who is using only hormone-contraceptive for birth control and has not been more that 1 year after Tubal ligation or menopause are excluded.
- •One who understood completed about this study after the explanation is given, decided to volunteer and gave written informed consent approved by IRB to participate in study in compliance with the requirement of the entire protocol.
排除标准
- •One who has record of hypersensitive reaction with Clozapine or other antipsychotic drug.
- •WBC count less than 4,000/ml or Absolute Neutrophil count less than 2,000/ml.
- •Administering hypertension drug or has orthostatic hypotension.
- •One who has clinical problem with kidney or liver and include following criteria: CCr < 50mL/min; BUN > 30 mg/dl; ALT 또는 AST > 3 x ULN; Total bilirubin > 2 x ULN; ALP > 2 x ULN.
- •Diagnosed to have other psychiatric or neurological problems other than Schizophrenia (e.g., Organic mental disorder, severe tardive dyskinesia, idiopathic Parkinson's disease, etc).
- •Record of Granulocytopenia or Myeloproliferative disorder in the past.
- •Record of stomach-related problems(active Crohn's disease, vital infectious intestine disease, ulcer, acute or chronic pancreatitis etc) or surgery which can affect absorption of study drug. However, simple appendectomy or herniotomy are exceptions.
- •Chronic Hepatitis B carrier, proof of Hepatitis C carrier or Hepatitis C antibody.
- •Immunodeficiency diseases such as HIV positive, AIDS, had bone marrow transplantation or has blood ammonia.
- •Record of seizure in 1 year before signing informed consent form or had administered anti-seizure drug before(e.g., Epilepsy, Convulsions, Myasthenia gravis, etc).
- •One who constantly drinks(> 21Units/week, 1Unit = 10g of pure alcohol) or cannot stop drinking alcohol during hospitalization period.
- •Smoking past 3 months before signing informed consent form or cannot stop smoking during hospitalization period.
- •One who cannot attend routine blood tests.
- •Bone marrow malfunction.
- •Mental illness, durg addicted or in coma.
- •One who has any kind of circulation imperfection and patient with depressed central nervous system.
- •Major kidney and heart problem(e.g. myocarditis).
- •Incurable epilepsy.
- •Paralytic intestinal obstruction.
- •Generic problems such as Lactose intolerance, Galactose intolerance, Lapp lactose deficiency, Glucose-Galactose absorption deficiency, etc.
- •Administered barbital-related drugs and drug metabolizing enzyme inducer and inhibitor in 1 month before starting the study.
- •One who had drugs that can affect on result of the study for past 10 days before the study start.
- •One who had whole blood donation in 2 months or blood component donation or transfusion in 1 month before signing the informed consent form.
- •Attended clinical tests or bioequivalence tests in 2 months before signing informed consent form.
- •Currently pregnant or breast-feeding or has possibility of pregnancy because one is not using medically approved contraception(Note: condoms, oral contraceptive, intrauterine device, abstinence etc).
- •One who is clinically significant by observations considered as unsuitable based on medical judgement by investigators.
研究组 & 干预措施
A Group
Experimental
1.1st Administration - DWCZP tablet 100mg Mutiple dose
2.2nd Administration - Clozaril tablet 100mg Mutiple dose
干预措施: DWCZP (Drug)
A Group
Experimental
1.1st Administration - DWCZP tablet 100mg Mutiple dose
2.2nd Administration - Clozaril tablet 100mg Mutiple dose
干预措施: Clozaril (Drug)
B Group
Experimental
1.1st Administration - Clozaril tablet 100mg Mutiple dose
2.2nd Administration - DWCZP tablet 100mg Mutiple dose
干预措施: DWCZP (Drug)
B Group
Experimental
1.1st Administration - Clozaril tablet 100mg Mutiple dose
2.2nd Administration - DWCZP tablet 100mg Mutiple dose
干预措施: Clozaril (Drug)
结局指标
主要结局
Maximum Concentration of Clozapine in Plasma
时间窗: Up to 12hours
次要结局
- Terminal Half Life of Clozapine in Plasma(Up to 12hours)
- Accumulation Rate of Clozapine in Plasma(Up tp 12hours)
- Time to Reach Maximum Concentration of Clozapine in Plasma(Up to 12hours)
研究者
研究点 (5)
Loading locations...
相似试验
Unknown
1 期
Study to Evaluate Drug-Drug Interaction of DWP16001 in Combination With DWC202001 and DWC202002 in Healthy Male AdultsHealthyNCT04343547Daewoong Pharmaceutical Co. LTD.34
已完成
3 期
A Study to Evaluate Efficacy and Safety Profile of Zabofloxacin Tablet 400mg and Moxifloxacin Tablet 400mgChronic Obstructive Pulmonary DiseaseNCT01658020Dong Wha Pharmaceutical Co. Ltd.345
已完成
1 期
The Pharmacokinetic Study of the Fixed-dose Combination of Micronized Fenofibrate and Pitavastatin CaHealthy Male VolunteersNCT02250976Hanlim Pharm. Co., Ltd.41
已完成
1 期
Pharmacokinetics/ Pharmacodynamics and Safety of DA-4001 in Healthy Male Subjects With Androgenic AlopeciaAndrogenic AlopeciaNCT02824380Dong-A ST Co., Ltd.14
已完成
1 期
Pharmacokinetics and Pharmacodynamics Study of Gemcabene in Healthy VolunteersHypercholesterolemiaNCT02587364NeuroBo Pharmaceuticals Inc.50